Poz | 6 hours ago
“HIV Treatment Works” is a new awareness campaign from the U.S. Centers for Disease Control and Prevention (CDC).
Hepatitis C treatment
HIVandhepatitis.com | 7 hours ago
A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.
Behaviour change interventions
Positive Lite | 7 hours ago
The most important group who should hear about treatment as prevention, undetectability, sero-sorting and all the other non-condom options, are those who have successfully avoided HIV thus far and are reluctant to get tested. In other words the vast majority of the LGBT population, because they are the ones who are getting the wrong end of the stick when they hear snippets of information about HIV.
Infojustice | 9 hours ago
Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.
Hepatitis C treatment
I-MAK | 9 hours ago
Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.
EATG | 10 hours ago
We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.
How HIV causes disease
Science Daily | 10 hours ago
We respond to infections in two fundamental ways. One is 'resistance,' where the body attacks the invading pathogen and reduces its numbers. Another, which is much less well understood, is 'tolerance,' where the body tries to minimize the damage done by the pathogen. A study using data from a large Swiss cohort of HIV-infected individuals gives us a glimpse into why some people cope with HIV better than others.
Medscape (requires registration) | 10 hours ago
The HIV Organ Policy Equity (HOPE) Act, which legalizes research into organ tranplants from HIV-positive donors to HIV-positive recipients, is less than a year old, but a new study already suggests the organs may be of poor quality.
Men who have sex with men (MSM)
Evening Standard | 10 hours ago
Lord Fowler told the Evening Standard: “We have come a long way. It [Section 28] was a great mistake and I think it’s now recognised as a great mistake and I would apologise for it. It was totally misjudged.”
BETA blog | 11 hours ago
Dr. Meredith Greene, fellow in the Division of Geriatrics at University of California, San Francisco, has spent her career working out how to integrate HIV services and geriatric care. “Traditionally, those areas haven’t overlapped a lot,” she explains—yet as individuals with HIV live longer with increasingly more effective and tolerable HIV therapies, she recognizes the importance of tailoring medical care services for older HIV-positive adults to their unique medical needs.